Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Exelixis and Boehringer Ingelheim ink autoimmune disease deal
June 2009
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.Exelixis Inc. and German pharmaceutical group Boehringer Ingelheim announced in May that they have established an exclusive, worldwide collaboration with the aim to discover, develop and commercialize autoimmune disease therapies. The collaboration is focused on the discovery of sphingosine-1-phosphate type 1 receptor (S1P1) agonists. Under the terms of the agreement, Exelixis will receive a $15 million upfront payment. In addition, Exelixis will potentially receive up to $339 million in milestone payments dependent on the successful achievement of development, regulatory and commercial program goals and royalties on sales of potential products commercialized under the collaboration. Exelixis and Boehringer Ingelheim will share responsibility for discovery activities and Boehringer Ingelheim will have sole responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.